SCHEMBL4257702

SCHEMBL4257702

O=C(Nc1ccc(-c2nc(-c3ccccc3)co2)c(Cl)c1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 4/20 0.60
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GRM4 Q14833 1/20 0.46
KCNK3 O14649 3/20 0.46
KCNK9 Q9NPC2 3/20 0.46
PTPN1 P18031 2/20 0.46
PTPN2 P17706 1/20 0.46
AGPAT2 O15120 1/20 0.46
ADORA1 P30542 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ACE2 Q9BYF1 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255803 0.89 SMO (0.78) SMOMAPTALDH1A1MEN1KMT2A
SCHEMBL4260779 0.86 SMO (0.64) SMORAB9ANPC1MAPTKDM4E
SCHEMBL4254599 0.80 SMO (0.64) SMORAB9ANPC1MAPTKDM4E
SCHEMBL4257047 0.79 SMO (0.66) SMORAB9ANPC1KDM4EALDH1A1
SCHEMBL4262816 0.76 NPC1 (0.62) SMORAB9ANPC1MAPTALDH1A1
SCHEMBL4255817 0.75 SMO (1.00) SMOMAPTALDH1A1MEN1KMT2A
SCHEMBL13878316 0.74 RAB9A (0.56) RAB9ANPC1MAPTKDM4EALDH1A1
SCHEMBL4254933 0.74 SMO (0.79) SMORAB9ANPC1MAPTKDM4E
SCHEMBL4242132 0.73 MEN1 (0.67) RAB9ANPC1MEN1KMT2AGRM4
SCHEMBL4254904 0.71 MAPT (0.51) SMORAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 SMO 1063/4885RAB9A 4455/4885NPC1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.